Tyrosine Metabolism
Tyrosine is one of the least soluble amino acids, and forms characteristic crystals upon precipitation. It derives from two sources, diet and hydroxylation of phenylalanine (. Fig. 18.1 ). Tyrosine is both glucogenic and ketogenic, since its catabolism, which proceeds predominantly in the liver cytosol, results in the formation of fumarate and acetoacetate. The first step of tyrosine catabolism is conversion into 4-hydroxyphenylpyruvate by cytosolic tyrosine aminotransferase. Transamination of tyrosine can also be accomplished in the liver and in other tissues by mitochondrial aspartate aminotransferase, but this enzyme plays only a minor role under normal conditions. The penultimate intermediates of tyrosine catabolism, maleylacetoacetate and fumarylacetoacetate, can be reduced to succinylacetoacetate, followed by decarboxylation to succinylacetone. The latter is the most potent known inhibitor of the heme biosynthetic enzyme, 5-aminolevulinic acid dehydratase (porphobilinogen synthase, . Fig. 36.1 ).
. Fig. 18.1 . The tyrosine catabolic pathway. 1, Tyrosine aminotransferase (deficient in tyrosinaemia type II); 2, 4-hydroxyphenylpyruvate dioxygenase (deficient in tyrosinaemia type III, hawkinsinuria, site of inhibition by NTBC); 3, homogentisate dioxygenase (deficient in alkaptonuria); 4, fumarylacetoacetase (deficient in tyrosinaemia type I); 5, aspartate aminotransferase; 6, 5-aminolevulinic acid (5-ALA) dehydratase (porphobilinogen synthase). Enzyme defects are depicted by solid bars across the arrows Five inherited disorders of tyrosine metabolism are known, depicted in Fig. 18 .1. Hereditary tyrosinaemia type I is characterised by progressive liver disease and renal tubular dysfunction with rickets. Hereditary tyrosinaemia type II (Richner-Hanhart syndrome) presents with keratitis and blisterous lesions of the palms and soles. Tyrosinaemia type III may be asymptomatic or associated with mental retardation. Hawkinsinuria may be asymptomatic or presents with failure to thrive and metabolic acidosis in infancy. In alkaptonuria symptoms of osteoarthritis usually appear in adulthood. Other inborn errors of tyrosine metabolism include oculocutaneous albinism caused by a deficiency of melanocyte-specific tyrosinase, converting tyrosine into DOPA-quinone; the deficiency of tyrosine hydroxylase, the first enzyme in the synthesis of dopamine from tyrosine; and the deficiency of aromatic L-amino acid decarboxylase, which also affects tryptophan metabolism. The latter two disorders are covered in 7 Chap. 29.
18.1
Hereditary Tyrosinaemia Type I (Hepatorenal Tyrosinaemia)
18.1.1

Clinical Presentation
The clinical manifestations of tyrosinaemia type 1 are very variable and an affected individual can present at any time from the neonatal period to adulthood. There is considerable variability of presentation even between members of the same family.
Clinically, tyrosinaemia type 1 may be classified based on the age at onset of symptoms, which broadly correlates with disease severity: an »acute« form that manifests before 6 months of age with acute liver failure; a »subacute« form presenting between 6 months and 1 year of age with liver disease, failure to thrive, coagulopathy, hepatosplenomegaly, rickets and hypotonia; and a more »chronic« form that presents after the first year with chronic liver disease, renal disease, rickets, cardiomyopathy and/or a porphyria-like syndrome. Treatment of tyrosinaemia type 1 with NTBC in the last decade (7 Sect. 18.1.5) has dramatically altered its natural history.
Hepatic Disease
The liver is the major organ affected in tyrosinaemia 1, and is a major cause of morbidity and mortality. Liver disease can manifest as acute hepatic failure, cirrhosis or hepatocellular carcinoma; all three conditions may occur in the same patient. The more severe forms of tyrosinaemia type 1 present in infancy with vomiting, diarrhoea, bleeding diathesis, hepatomegaly, jaundice, hypoglycaemia, edema and ascites. Typically, liver synthetic function is most affected and in particular, coagulation is markedly abnormal compared with other tests of liver function. Sepsis is common and early hypophosphataemic bone disease may be present secondary to renal tubular dysfunction. Acute liver failure may be the initial presenting feature or may occur subsequently, precipitated by intercurrent illnesses as »hepatic crises« which are associated with hepatomegaly and coagulopathy. Mortality is high in untreated patients [1] .
Chronic liver disease leading to cirrhosis eventually occurs in most individuals with tyrosinaemia 1 -both as a late complication in survivors of early-onset disease and as a presenting feature of the later-onset forms. The cirrhosis is usually a mixed micromacronodular type with a variable degree of steatosis [2] . There is a high risk of carcinomatous transformation within these nodules [1, 3] . Unfortunately, the differences in size and fat content of the nodules make it difficult to detect malignant changes (7 Sect. 18.1.5).
Renal Disease
A variable degree of renal dysfunction is detectable in most patients at presentation, ranging from mild tubular dysfunction to renal failure. Proximal tubular disease is very common and can become acutely exacerbated during hepatic crises. Hypophosphataemic rickets is the most common manifestation of proximal tubulopathy but generalised aminoaciduria, renal tubular acidosis and glycosuria may also be present [4] . Other less common renal manifestations include distal renal tubular disease, nephrocalcinosis and reduced glomerular filtration rates.
Neurological Manifestations
Acute neurological crises can occur at any age. Typically, the crises follow a minor infection associated with anorexia and vomiting, and occur in two phases: an active period lasting 1-7 days characterised by painful parasthesias and autonomic signs that may progress to paralysis, followed by a recovery phase over several days [5] . Complications include seizures, extreme hyperextension, self-mutilation, respiratory paralysis and death.
Other Manifestations
Cardiomyopathy is a frequent incidental finding, but may be clinically significant [6] . Asymptomatic pancreatic cell hypertrophy may be detected at presentation, but hyperinsulinism and hypoglycaemia are rare [7] .
18.1.2
Metabolic Derangement
Tyrosinaemia type 1 is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH), which is mainly expressed in the liver and kidney. The compounds immediately upstream from the FAH reaction, maleylaceto acetate (MAA) and fumarylacetoacetate (FAA), and their derivatives, succinylacetone (SA) and succinylacetoacetate (SAA)
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accumulate and have important pathogenic effects. The effects of FAA and MAA occur only in the cells of the organs in which they are produced; these compounds are not found in body fluids of patients. On the other hand, their derivatives, SA and SAA are readily detectable in plasma and urine and have widespread effects.
FAA, MAA and SA disrupt sulfhydryl metabolism by forming glutathione adducts, thereby rendering cells susceptible to free radical damage [8, 9] . Disruption of sulfhydryl metabolism is also believed to cause secondary deficiency of two other hepatic enzymes, 4-hydroxyphenylpyruvate dioxygenase and methionine adenosyltransferase, resulting in hypertyrosinemia and hypermethioninemia. Additionally, FAA and MAA are alkylating agents and can disrupt the metabolism of thiols, amines, DNA and other important intracellular molecules. As a result of these widespread effects on intracellular metabolism, hepatic and renal cells exposed to high levels of these compounds undergo either apoptotic cell death or a significant alteration of gene expression [10] [11] [12] . In patients who have developed cirrhosis, self-induced correction of the genetic defect and the enzyme abnormality occurs within some nodules [13] . The clinical expression of hepatic disease may correlate inversely with the extent of mutation reversion in regenerating nodules [14] . The mechanisms that underlie the development of hepatocellular carcinoma within nodules are poorly understood.
SA is a potent inhibitor of the enzyme 5-ALA dehydratase. 5-ALA, a neurotoxic compound, accumulates and is excreted at high levels in patients with tyrosinemia type 1 and is believed to cause the acute neurological crises seen during decompensation [5] . SA is also known to disrupt renal tubular function, heme synthesis and immune function [15] [16] [17] .
18.1.3
Genetics
Hereditary tyrosinaemia type I is inherited as an autosomal recessive trait. The FAH gene has been localised to 15q 23-25 and more than 40 mutations have been reported [18] . The most common mutation, IVS12+5(g-a), is found in about 25 % of the alleles worldwide and is the predominant mutation in the French-Canadian population in which it accounts for >90 % of alleles. Another mutation, IVS6-1(g-t) is found in around 60 % of alleles in patients from the Mediterranean area. Other FAH mutations are common within certain ethnic groups: W262X in Finns, D233V in Turks, and Q64H in Pakistanis. There is no clear genotypephenotype correlation [19] ; spontaneous correction of the mutation within regenerative nodules may influence the clinical phenotype [14] . A pseudodeficiency mutation, R341W, has been reported in healthy individuals who have in vitro FAH activity indistinguishable from patients with type 1 tyrosinaemia [20] . The frequency of this mutation in various populations is unknown but it has been found in many different ethnic groups.
18.1.4
Diagnostic Tests
In symptomatic patients, biochemical tests of liver function are usually abnormal. In particular, liver synthetic function is severely affected -coagulopathy and/or hypoalbuminemia are often present even if other tests of liver function are normal. In most acutely ill patients, -fetoprotein levels are greatly elevated. A Fanconi-type tubulopathy is often present with aminoaciduria, phosphaturia and glycosuria, and radiological evidence of rickets may be present.
Elevated levels of succinylacetone in dried blood spots, plasma or urine are pathognomonic of tyrosinaemia type 1.
Other metabolite abnormalities that are suggestive of the diagnosis include elevated plasma levels of tyrosine, phenylalanine and methionine, reduced erythrocyte 5-aminolevulinate dehydratase activity and increased urinary 5-ALA excretion.
Confirmation of the diagnosis requires either enzyme assay or mutation analysis. FAH assays may be performed on liver biopsy, fibroblasts, lymphocytes or dried blood spots [21] [22] [23] . Falsely elevated enzyme results may be obtained on liver biopsy if a reverted nodule is inadvertently assayed. Enzyme assay results should therefore be interpreted in the context of the patients' clinical and biochemical findings.
Newborn Screening
Screening using tyrosine levels alone has been used in the past and has resulted in very high false positive and false negative rates [24] . More recently, methods based on the inhibitory effects of SA on porphobilinogen synthase, either alone or in combination with tyrosine levels have successfully reduced false-positive rates [25] . Molecular screening is possible in populations in which one or few mutations account for the majority of cases.
Prenatal Diagnosis
If the causative mutations in a pregnancy at risk are known, antenatal diagnosis is best performed by mutation analysis on chorionic villus sampling (CVS) or amniocytes. Alternative methods include FAH assay on CVS [26] or amniocytes [27] and determination of SA levels in amniotic fluid [28] . However, FAH is expressed at low levels in chorionic tissue and interpretation of results may be difficult. Assay for elevated SA levels in amniotic fluid is very reliable and can be performed as early as 12 weeks; however, occasional affected pregnancies have reported normal SA amniotic fluid levels [29] . When mutation analysis is not available for prenatal diagnosis, we currently use a strategy combining initial screening for the common pseudodeficiency mutation and FAH assay on CVS at 10 weeks; pregnancies that have low FAH activity on CVS subsequently undergo amniocentesis for amniotic fluid SA levels at 11-12 weeks for confirmation.
18.1.5
Treatment and Prognosis
Historically, tyrosinaemia type I was treated with a tyrosine and phenylalanine restricted diet, with or without liver transplantation. In 1992 a new drug, 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase was introduced (. Fig. 18.1, enzyme 2) ; it has revolutionised the treatment of type 1 tyrosinaemia and is now the mainstay of therapy [30] .
NTBC
The rationale for the use of NTBC is to block tyrosine degradation at an early step so as to prevent the production of toxic down-stream metabolites such as FAA, MAA and SA; the levels of tyrosine, 4-hydroxyphenyl-pyruvate and -lactate concomitantly increase (. Fig. 18.1) . The Gothenberg multicentre study provides the major experience of NTBC treatment in tyrosinaemia type 1 [31] . Over 300 patients have been treated; of these, over 100 have been treated for over 5 years. NTBC acts within hours of administration and has a long half-life of about 54 hours [32] . In patients presenting acutely with hepatic decompensation, rapid clinical improvement occurs in over 90% with normalisation of prothrombin time within days of starting treatment. Other biochemical parameters of liver function may take longer to normalise: -fetoprotein concentrations may not normalise for up to several months after starting treatment. NTBC is recommended in an initial dose of 1 mg/kg body weight per day [31] . Individual dose adjustment is subsequently based on the biochemical response and the plasma NTBC concentration. Dietary restriction of phenylalanine and tyrosine is necessary to prevent the known adverse effects of hypertyrosinaemia (see tyrosinaemia type II). We currently aim to maintain tyrosine levels between 200 and 400 µmol/l using a combination of a protein-restricted diet and phenylalanine and tyrosine free amino acid mixtures.
A small proportion of acutely presenting patients (<10%) do not respond to NTBC treatment; in these patients, coagulopathy and jaundice progress and mortality is very high without urgent liver transplantation.
Adverse events of NTBC therapy have been few. Transient thrombocytopenia and neutropenia and transient eye symptoms (burning/photophobia/corneal erosion/corneal clouding) have been reported in a small proportion of patients [31] . The short-to medium-term prognosis in responders appears to be excellent. Hepatic and neurological decompensations are not known to occur on NTBC treatment, and clear deterioration of chronic liver disease is rare. Renal tubular dysfunction responds well to NTBC therapy, but long-standing renal disease may be irreversible. Neu rological crises are rarely seen in patients treated with NTBC.
The risk of hepatocellular carcinoma appears to be much reduced in patients started early on NTBC treatment. In particular, the risk is very low if treatment is commenced before 6 months of age. In patients started on NTBC after 6 months of age, the risk of developing hepatocellular carcinoma increases with the age at which treatment is introduced; if NTBC is introduced after 2 years of age, the risk may not be much different from that in historical controls (. Table 18 .1). It remains to be determined whether early NTBC treatment can prevent liver cancer in the long term. Studies on the animal mouse models suggest that late hepatocellular carcinoma may occur even if NTBC treatment is started at birth [10, 33] ; careful long-term vigilance is therefore necessary in all patients.
The long-term neuropsychological outcome of NTBCtreated patients with tyrosinaemia type 1 is also unclear. Many patients appear to have significant learning difficulties; cognitive deficits affecting performance abilities more than verbal abilities have been found in many patients on psychological testing [34] . The etiology of these cognitive deficits is uncertain; whether they are related to NTBC . 
treatment or high tyrosine levels or are a feature of tyrosinemia 1 per se is unknown. Monitoring of patients on NTBC treatment should include regular blood tests for liver function, blood counts, clotting studies, alpha fetoprotein, SA, plasma PBG synthase activity, 5-ALA, NTBC levels and amino acid profile; tests of renal tubular and glomerular function; urinary SA and 5-ALA; and hepatic imaging by ultrasound and CT/ MRI. Blood levels of phenylalanine and tyrosine should be frequently monitored and the diet supervised closely.
Liver Transplantation
Liver transplantation has been used for over two decades in treating type 1 tyrosinaemia, and appears to cure the hepatic and neurological manifestations [35, 36] . However, even in optimal circumstances, it is associated with approximately 5-10% mortality and necessitates lifelong immunosuppressive therapy. Therefore, at present liver transplantation in type 1 tyrosinaemia is restricted to patients with acute liver failure who fail to respond to NTBC therapy, and in patients with suspected hepatocellular carcinoma. Currently, there is no non-invasive way of reliably detecting malignancy within hepatic nodules. Regular monitoring of plasma -fetoprotein levels and of hepatic architecture on computerized tomography (CT) or magnetic resonance imaging (MRI) are essential; liver transplantation has to be considered if these investigations suggest malignant transformation. Other situations in which liver transplantation may be considered relate to the irreversible manifestations of chronic liver disease, such as severe portal hypertension, growth failure and poor quality of life.
The long-term impact of liver transplantation on renal disease in tyrosinaemia type 1 is not fully known. Tubular dysfunction improves in most patients, but does not always normalise. Glomerular function generally remains stable but may be affected by nephrotoxic immunotherapy [34, 37] . Urinary SA excretion is much reduced after liver transplantation but does not normalise, presumably due to continued renal production [38] ; whether this affects renal function long-term and predisposes to renal malignancy is unknown. In patients with severe hepatic and renal disease, combined liver and kidney transplantation should be considered.
Dietary Treatment
Before the advent of NTBC therapy, dietary protein restriction was the only available treatment for tyrosinaemia type 1 apart from liver transplantation. Dietary treatment was helpful in relieving the acute symptoms and perhaps slowing disease progression, but it did not prevent the acute and chronic complications including hepatocellular carcinoma. Currently, dietary therapy alone is not recommended, but is used in conjunction with NTBC therapy to prevent the complications related to hypertyrosinaemia. Ocular and dermatological complications are not believed to occur below plasma tyrosine levels of 800 mol/l; however, lower levels (200-400 mol/l) are usually recommended due to possible effects of hypertyrosinaemia on cognitive outcome. Whether dietary treatment is used alone or in conjunction with NTBC, the principle is the same: natural protein intake is restricted to provide just enough phenylalanine plus tyrosine to keep plasma tyrosine levels <400 mol/l; the rest of the normal daily protein requirement is given in the form of a phenylalanine-and tyrosine-free amino acid mixture. Some patients develop very low phenylalanine levels with this regimen and may require phenylalanine supplements [39] .
Supportive Treatment
In the acutely ill patient supportive treatment is essential. Clotting factors, albumin, electrolytes and acid/base balance should be closely monitored and corrected as necessary. Tyrosine and phenylalanine intake should be kept to a minimum during acute decompensation. Addition of vitamin D, preferably 1,25 hydroxy vitamin D 3 or an analogue, may be required to treat rickets. Infections should be treated aggressively.
Pregnancy
To date, no published data on pregnancies in patients on NTBC treatment is available; one pregnancy in a livertransplanted tyrosinaemia type 1 patient has had a favourable outcome [40] .
18.2
Hereditary Tyrosinaemia Type II (Oculocutaneous Tyrosinaemia, Richner-Hanhart Syndrome)
18.2.1
Clinical Presentation
The disorder is characterised by ocular lesions (about 75% of the cases), skin lesions (80%), and neurological complications (60%), or any combination of these [41] . The disorder usually presents in infancy but may become manifest at any age.
Eye symptoms are often the presenting problem and may start in the first months of life with photophobia, lacrimation and intense burning pain [42] . The conjunctivae are inflamed and on slit-lamp examination herpetic-like corneal ulcerations are found. The lesions stain poorly with fluorescein. In contrast with herpetic ulcers, which are usually unilateral, the lesions in tyrosinaemia type II are bilateral. Neovascularisation may be prominent. Untreated, serious damage may occur with corneal scarring, visual impairment, nystagmus and glaucoma.
Skin lesions specifically affect pressure areas and most commonly occur on the palms and soles [43, 44] . They begin as blisters or erosions with crusts and progress to painful, nonpruritic hyperkeratotic plaques with an ery-thematous rim, typically ranging in diameter from 2 mm to 3 cm.
The neurological complications are highly variable: some patients are developmentally normal whilst others have variable degrees of developmental retardation. More severe neurological problems, including microcephaly, seizures, self-mutilation and behavioural difficulties have also been described [45] .
It should be noted that the diagnosis of tyrosinaemia type II has only been confirmed by enzymatic and/or molecular genetic analysis in a minority of the described cases and it is possible that some of the patients actually have tyrosinaemia type III.
18.2.2
Metabolic Derangement
Tyrosinaemia type II is due to a defect of hepatic cytosolic tyrosine aminotransferase (. Fig. 18.1, enzyme 1) . As a result of the metabolic block, tyrosine concentrations in serum and cerebrospinal fluid are markedly elevated. The accompanying increased production of the phenolic acids 4-hydroxyphenyl-pyruvate, -lactate and -acetate (not shown in . Fig. 18.1 ) may be a consequence of direct deamination of tyrosine in the kidneys, or of tyrosine catabolism by mitochondrial aminotransferase (. Fig. 18.1 ). Corneal damage is thought to be related to crystallization of tyro sine in the corneal epithelial cells, which results in disruption of cell function and induces an inflammatory response. Tyrosine crystals have not been observed in the skin lesions. It has been suggested that excessive intracellular tyro sine enhances cross-links between aggregated tonofilaments and modulates the number and stability of microtubules [46] . As the skin lesions occur on pressure areas, it is likely that mechanical factors also play a role. The etiology of the neurological manifestations is unknown, but it is believed that hypertyrosinaemia may have a role in pathogenesis.
18.2.3
Genetics
Tyrosinaemia type II is inherited as an autosomal recessive trait. The gene is located at 16q22.1-q22.3. Twelve different mutations have so far been reported in the tyrosine aminotransferase gene [35] . Prenatal diagnosis has not been reported.
Diagnostic Tests
Plasma tyrosine concentrations are usually above 1200 mol/ l. When the tyrosinaemia is less pronounced a diagnosis of tyrosinaemia type III should be considered (7 Sect. 18.3) . Urinary excretion of the phenolic acids 4-hydroxyphenylpyruvate, -lactate, -acetate is highly elevated and N-acetyltyrosine and 4-tyramine are also increased. The diagnosis can be confirmed by enzyme assay on liver biopsy or by mutation analysis.
18.2.5
Treatment and Prognosis
Treatment consists of a phenylalanine and tyrosine-restricted diet, and the skin and eye symptoms resolve within weeks of treatment [44, 47] . Generally, skin and eye symptoms do not occur at tyrosine levels < 800 mol/l; however, as hypertyrosinaemia may be involved in the pathogenesis of the neurodevelopmental symptoms, it may be beneficial to maintain much lower levels [48] . We currently aim to maintain plasma tyrosine levels of 200-400 mol/l using a combination of a protein-restricted diet and a phenyl alanine and tyrosine free amino acid mixture. Growth and nutritional status should be regularly monitored.
Pregnancy
There have been several reports of pregnancies in patients with tyrosinaemia type II: some have suggested that untreated hypertyrosinaemia may result in fetal neurological abnormalities such as microcephaly, seizures and mental retardation [45, 49, 50] ; however, other pregnancies have reported normal fetal outcome [45, 51] . In view of the uncertainty regarding possible fetal effects of maternal hypertyrosinaemia, dietary control of maternal tyrosine levels during pregnancy is recommended [50] .
18.3
Hereditary Tyrosinaemia Type III
18.3.1
Clinical Presentation
Only 13 cases of tyrosinaemia type III have been described and the full clinical spectrum of this disorder is unknown [52] . Many of the patients have presented with neurological symptoms including intellectual impairment, ataxia, increased tendon reflexes, tremors, microcephaly and seizures; some have been detected by the finding of a high tyrosine concentration on neonatal screening. The most common long-term complication has been intellectual impairment, found in 75% of the reported cases. None of the described cases have developed signs of liver disease in the long-term. Eye and skin lesions have not been reported so far, but as oculocutaneous symptoms are known to occur in association with hypertyrosinaemia it is reasonable to be aware of this possibility.
18.3.2
Metabolic Derangement
Tyrosinaemia type III is due to deficiency of 4-hydroxyphenylpyruvate dioxygenase (HPD) (. Fig. 18.1, enzyme 2 ),
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which is expressed in liver and kidney. As a result of the enzyme block there is an increased plasma tyrosine concentration and increased excretion in urine of 4-hydroxyphenyl-pyruvate and its derivatives 4-hydroxyphenyllactate and 4-hydroxyphenyl-acetate. The aetiology of the neurological symptoms is not known, but they may be related to hypertyrosinaemia as in tyrosinaemia types 1 and 2.
18.3.3
Genetics
Tyrosinaemia type III follows autosomal recessive inheri tance. The HPD gene has been localised to 12q24-qter and 5 mutations associated with tyrosinaemia III have been described [35] . There is no apparent genotype-phenotype correlation; some patients with enzymatically defined HPD deficiency do not have identifiable mutations in the HPD gene [52, 53] .
18.3.4
Diagnostic Tests
Elevated plasma tyrosine levels of 300-1300 mol/l have been found in the described cases at diagnosis. Elevated urinary excretion of 4-hydroxyphenyl-pyruvate, -lactate and -acetate usually accompanies the increased plasma tyrosine concentration. Diagnosis can be confirmed by enzyme assay in liver or kidney biopsy specimens or by mutation analysis.
18.3.5
Treatment and Prognosis
At present, tyrosinemia type III appears to be associated with intellectual impairment in some cases, but not in others. It is unknown whether lowering plasma tyrosine levels will alter the natural history. Amongst the patients described, the cases detected by neonatal screening and treated early appear to have fewer neurological abnormalities than those diagnosed on the basis of neurological symptoms [52] ; whether this is due to ascertainment bias or due to therapeutic intervention is unclear. Until there is a greater understanding of the etiology of the neurological compli cations of tyrosinaemia type III, it is reasonable to treat patients with a low-phenylalanine and tyrosine diet. We currently recommend maintaining plasma tyrosine levels between 200 and 400 mol/l. No pregnancy data is available to date.
18.4
Transient Tyrosinaemia
Transient tyrosinaemia is one of the most common amino acid disorders, and is believed to be caused by late fetal maturation of 4-hydroxyphenylpyruvate dioxygenase (. Fig. 18.1, enzyme 2) . It is more common in premature infants than full term newborns. The level of protein intake is an important etiological factor: the incidence of transient tyrosinaemia has fallen dramatically in the last 4 decades, concomitant with a reduction in the protein content of newborn formula milks. Transient tyrosinaemia is clinically asymptomatic. Tyrosine levels are extremely variable, and can exceed 2000 mol/l. Hypertyrosinaemia usually resolves spontaneously by 4-6 weeks; protein restriction to less than 2 g/kg/day with or without vitamin C supplementation results in more rapid resolution in most cases. Although the disorder is generally considered benign, some reports have suggested that it may be associated with mild intellectual deficits in the long term [54, 55] . However, large systematic studies have not been performed.
18.5
Alkaptonuria
18.5.1
Clinical Presentation
Some cases of alkaptonuria are diagnosed in infancy due to darkening of urine when exposed to air. However, clinical symptoms first appear in adulthood. The most prominent symptoms relate to joint and connective tissue involvement; significant cardiac disease and urolithiasis may be detected in the later years [56] .
The pattern of joint involvement resembles osteoarthritis. In general, joint disease tends to be worse in males than in females. The presenting symptom is usually either limitation of movement of a large joint or low back pain starting in the 3rd or 4th decade. Spinal involvement is progressive and may result in kyphosis, limited spine movements and height reduction. On X-ray examination, narrowing of the disk spaces, calcification and vertebral fusion may be evident. In addition to the spine, the large weight-bearing joints such as the hips, knees and ankles are usually involved. Radiological abnormalities may range from mild narrowing of the joint space to destruction and calcification. Synovitis, ligament tears and joint effusions have also been described. The small joints of the hands and feet tend to be spared. Muscle and tendon involvement is common: thickened Achilles tendons may be palpable, and tendons and muscles may be susceptible to rupture with trivial trauma. The clinical course is characterised by episodes of acute exacerbation and progressive joint disability; joint replacement for chronic pain may be required. Physical disability increases with age and may become very severe by the 6th decade.
A greyish discoloration (ochre on microscopic examination, thus the name ochronosis) of the sclera and the ear cartilages usually appears after 30 years of age. Subsequently, dark coloration of the skin particularly over the nose, cheeks and in the axillary and pubic areas may become evident. Cardiac involvement probably occurs in most patients eventually; aortic or mitral valve calcification or regurgi-tation and coronary artery calcification is evident on CT scan and echocardiography in about 50% of patients by the 6th decade [56] . A high frequency of renal and prostatic stones has also been reported.
18.5.2
Metabolic Derangement
Alkaptonuria was the first disease to be interpreted as an inborn error of metabolism in 1902 by Garrod [57] . It is caused by a defect of the enzyme homogentisate dioxygenase (. Fig. 18.1, enzyme 3) , which is expressed mainly in the liver and the kidneys. There is accumulation of homogentisate and its oxidised derivative benzoquinone acetic acid, the putative toxic metabolite and immediate precursor to the dark pigment, which gets deposited in various tissues. The relationship between the pigment deposits and the systemic manifestations is not known. It has been proposed that the pigment deposit may act as a chemical irritant [58] ; alternatively, inhibition of some of the enzymes involved in connective tissue metabolism by homogentisate or benzoquinone acetic acid may have a role in pathogenesis [59] .
18.5.3
Genetics
Alkaptonuria is an autosomal recessive disorder. The gene for homogentisate oxidase has been mapped to chromosome 3q2, and over 40 mutations have been identified [35] . The estimated incidence is between 1:250 000 and 1:1 000 000 live births.
18.5.4
Diagnostic Tests
Alkalinisation of the urine from alkaptonuric patients results in immediate dark brown coloration of the urine. Excessive urinary homogentisate also results in a positive test for reducing substances. Gas chromatography -mass spectrometry (GC-MS) based organic acid screening methods can specifically identify and quantify homogentisic acid. Homogentisate may also be quantified by HPLC [60] and by specific enzymatic methods [61].
18.5.5
Treatment and Prognosis
A number of different approaches have been used to attempt treatment. Dietary restriction of phenylalanine and tyrosine intake reduces homogentisate excretion, but compliance is a major problem as the diagnosis is usually made in adults [62] . Ascorbic acid prevents the binding of 14 C-homogentisic acid to connective tissue in rats [63] and reduces the excretion of benzoquinone acetic acid in urine [64] . Administration of the drug NTBC also reduces urinary homogentisate excretion; the concomitant hypertyrosinaemia requires dietary adjustment to prevent ocular, cutaneous and neurological complications [56] . None of these therapies have been subjected to long-term clinical trials, and currently, no treatment can be recommended as being effective in preventing the late effects of alkaptonuria.
To date, there is no published data on pregnancies in patients with alkaptonuria.
18.6
Hawkinsinuria 18.6.1
Clinical Presentation
This rare condition, which has only been described in four families [65] [66] [67] , is characterised by failure to thrive and metabolic acidosis in infancy. After the first year of life the condition appears to be asymptomatic. Early weaning from breastfeeding seems to precipitate the disease; the condition may be asymptomatic in breastfed infants.
18.6.2
Metabolic Derangement
The abnormal metabolites produced in hawkinsinuria (hawkinsin (2-cysteinyl-1,4-dihydroxycyclohexenylacetate) and 4-hydroxycycloxylacetate) are thought to derive from an incomplete conversion of 4-hydroxyphenylpyruvate to homogentisate caused by a defect 4-hydroxyphenylpyruvate dioxygenase (. Fig. 18.1, enzyme 2) . Hawkinsin is thought to be the product of a reaction of an epoxide intermediate with glutathione, which may be depleted. The metabolic acidosis is believed to be due to 5-oxoproline accumulation secondary to glutathione depletion.
18.6.3
Genetics
Unlike most other inborn errors of metabolism, hawkinsinuria shows autosomal dominant inheritance. The mole cular basis of the condition is unknown. It is believed that a specific mutation or a limited number of mutations in the 4-hydroxyphenylpyruvate dioxygenase gene can partially disrupt enzyme activity and lead to the production of hawkinsin and 4-hydroxycyclohexylacetate. Neither the enzymatic defect nor the molecular genetics have been studied in detail.
18.6.4
Diagnostic Tests
Identification of urinary hawkinsin or 4-hydroxycyclohexylacetate by GC-MS is diagnostic [67] . Hawkinsin is a ninhydrin-positive compound, which appears between urea and threonine in ion-exchange chromatography of 18.6 · Hawkinsinuria urine amino acids [68] . Increased excretion of 4-hydroxycyclohexylacetate is detected on urine organic acids analysis. In addition to hawkinsinuria there may be moderate tyrosinaemia, increased urinary 4-hydroxyphenylpyruvate and 4-hydroxyphenyllactate, metabolic acidosis and 5-oxoprolinuria during infancy. 4-Hydroxycyclohexylacetate is usually detectable only after infancy.
18.6.5
Treatment and Prognosis
Symptoms in infancy respond to a return to breastfeeding or a diet restricted in tyrosine and phenylalanine along with vitamin C supplementation. The condition is asymptomatic after the first year of life and affected infants are reported to have developed normally.
